#### Edgar Filing: VioQuest Pharmaceuticals, Inc. - Form 4

VioQuest Ph Form 4 July 13, 2007	armaceuticals, Inc.						
FORM			AITIES AND EXCHANGE	COMUCCION	т	PPROVAL	
Check thi if no long subject to Section 1 Form 4 o	UNITED STAT	OMB Number:	3235-0287				
	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					January 31, 2005 average irs per 0.5	
Form 5 obligation may cont <i>See</i> Instru 1(b).	$\frac{18}{100}$ Section $17(a)$ of the section						
(Print or Type F	Responses)						
	ddress of Reporting Person	2. Issuer Symbol	2. Issuer Name <b>and</b> Ticker or Trading Symbol		5. Relationship of Reporting Person(s) to Issuer		
		VioQue [VQPH]	st Pharmaceuticals, Inc. ]	(Check all applicable)			
(Last)	(First) (Middle)	(Month/D	-	X Director 10% Owner X Officer (give title Other (specify below) below)			
787 SEVEN FLOOR	TH AVENUE, 48TH	07/11/20	007		Secretary		
	(Street)		ndment, Date Original hth/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
NEW YORI	K, NY 10019			Form filed by M Person	More than One R	eporting	
(City)	(State) (Zip)	Tabl	e I - Non-Derivative Securities A	equired, Disposed of	f, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date 2A. 1 (Month/Day/Year) Exec any (Mon		3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or	Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock, par			Code V Amount (D) Price	(Instr. 3 and 4)			
value \$0.001 per share				719,335 <u>(1)</u>	I	By Trust	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Edgar Filing: VioQuest Pharmaceuticals, Inc. - Form 4

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exerci Expiration Dat (Month/Day/Y	te	7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount o Number o Shares
Stock Option	\$ 1.96					(3)	10/28/2013	Stock Option	12,900
Warrant	\$ 1.41					10/18/2005	10/18/2010	Common Stock	144,00
Stock Option	\$ 0.38	07/11/2007		А	100,000	(2)	07/11/2017	Common Stock	100,000

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships				
	Director	10% Owner	Officer	Other	
ROCAMBOLI STEPHEN 787 SEVENTH AVENUE, 48TH FLOOR NEW YORK, NY 10019	Х		Secretary		
<b>O</b> !					

### Signatures

/s/ Stephen C. Rocamboli	07/13/2007
**Signature of Reporting	Date

Person

Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 102,699 shares of common stock of VioQuest Pharmaceuticals, Inc. that were previously acquired and are held directly by the Reporting Person.
- (2) One-third of the option is immediately exercisable, and the remaining vests in two equal installments on 7/11/08 and 7/11/09.
- (3) The option became exercisable in three equal installments beginning October 28, 2004.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.